Adaptimmune Therapeutics PLC Quarterly Debt-to-equity in % from Q3 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Adaptimmune Therapeutics PLC quarterly Debt-to-equity history and growth rate from Q3 2016 to Q3 2024.
  • Adaptimmune Therapeutics PLC Debt-to-equity for the quarter ending September 30, 2024 was 391 %, a 69.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 391 +161 +69.9% Sep 30, 2024
Q2 2024 367 +148 +67.9% Jun 30, 2024
Q1 2024 324 +106 +48.6% Mar 31, 2024
Q4 2023 258 +64.2 +33.2% Dec 31, 2023
Q3 2023 230 +72.4 +45.9% Sep 30, 2023
Q2 2023 218 +102 +86.9% Jun 30, 2023
Q1 2023 218 +134 +160% Mar 31, 2023
Q4 2022 194 +137 +239% Dec 31, 2022
Q3 2022 158 +120 +323% Sep 30, 2022
Q2 2022 117 +84.2 +257% Jun 30, 2022
Q1 2022 83.9 +54.6 +186% Mar 31, 2022
Q4 2021 57.1 +25.3 +79.7% Dec 31, 2021
Q3 2021 37.4 +4.01 +12% Sep 30, 2021
Q2 2021 32.7 -4.53 -12.2% Jun 30, 2021
Q1 2021 29.3 -12.7 -30.2% Mar 31, 2021
Q4 2020 31.8 -0.94 -2.87% Dec 31, 2020
Q3 2020 33.3 +9.16 +37.9% Sep 30, 2020
Q2 2020 37.3 Jun 30, 2020
Q1 2020 41.9 Mar 31, 2020
Q4 2019 32.7 Dec 31, 2019
Q3 2019 24.2 Sep 30, 2019
Q4 2017 30.2 +4.49 +17.4% Dec 31, 2017
Q3 2017 30.4 +8.9 +41.4% Sep 30, 2017
Q2 2017 28.5 Jun 30, 2017
Q1 2017 28.1 Mar 31, 2017
Q4 2016 25.7 Dec 31, 2016
Q3 2016 21.5 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.